About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3850443
Allelic
Composition
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gth mutation (3 available); any Nf2 mutation (57 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (145 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• a few following adenoviral cre treatment

muscle
• in 7% of mice following adenoviral cre treatment

nervous system

reproductive system
• in 7% of mice following adenoviral cre treatment

mortality/aging
• following adenoviral cre treatment, median survival time is 135 days

neoplasm
• following adenoviral cre treatment, 86% of mice develop thoracic tumors (including malignant mesotheliomas, 45 of 55; rhabdomyosarcomas, 2 of 55; and schwannomas, 1 of 55)
• following adenoviral cre treatment, mice develop either non-aggressive epitheloid or mixed tumors with confined invasion of the visceral pleural or (sarcomatoid) tumors with strong invasion of visceral and parietal pleura
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus
• following adenoviral cre treatment, 11% of mice develop aspecific tumors not induced by adeno-cre treatment
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles
• a few following adenoviral cre treatment
• in 7% of mice following adenoviral cre treatment
• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles

liver/biliary system
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

Mouse Models of Human Disease
OMIM ID Ref(s)
Mesothelioma, Malignant; MESOM 156240 J:132943


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/20/2016
MGI 6.05
The Jackson Laboratory